Classic Hodgkin lymphoma

Abstract

Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15–39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by extension, clinical outcomes have improved dramatically with 5‐year overall survival (OS) approaching 90% today. [1](#ref‐0001) Advances in understanding HL biology have additionally facilitated development of targeted agents and immunotherapy which have further improved short and long‐term outcomes. Despite continued improvements in up‐front and salvage therapy, long‐term survivors of HL experience several treatment‐associated late toxicities, thus, along with efforts to improve therapeutic efficacy, efforts to reduce late effects remain a high‐priority in the field.

Antibody–Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab–Vedotin Exert Anti-Lymphoma and Immunostimulating Effects

“…Also, only Bre-Ved-ZA can trigger the expansion of a subset of potent antitumor T-lymphocytes (Vδ2 T-cells), which can kill some CD30 + HL-cell lines efficiently. The CD30 antigen is expressed on HL and some anaplastic lymphomas, and Bre-Ved is a therapeutic tool for these diseases [27][28][29][30][31][32][33][34]. The ADC can hit a molecular target with high selectivity, mainly expressed in tumor cells [35][36][37].…”

“…Anyway, to propose the use of Bre-Ved-ZA ADC to trigger the activation of Vδ2 T-cells against lymphoma cells, this ADC should be further supplemented by an activating cytokine such as IL2 in our experimental system. This limitation could be overcome in the HL microenvironment by the presence of immunostimulating cytokines [27][28][29][30][31][32][33][34].…”